Results 251 to 260 of about 1,289,148 (397)

The Vocabulary of Health

American Journal of Public Health and the Nations Health, 1961
openaire   +4 more sources

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

Integrating AI in Pakistani ESL classrooms: Teachers' practices, perspectives, and impact on student performance. [PDF]

PLoS One
Saleem T, Saleem A, Aslam DM.
europepmc   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

Training and horse management in India, with Hindustanee vocabulary and C.T.C. weights for age and class

, 1893
M. Horace Hayes
openalex   +2 more sources

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

Breaking data silos: incorporating the DICOM imaging standard into the OMOP CDM to enable multimodal research. [PDF]

J Am Med Inform Assoc
Park WY, Sippel Schmidt T, Salvador G, O'Donnell K, Genereaux B, Jeon K, You SC, Dewey BE, Nagy P, Alzheimer’s Disease Neuroimaging Initiative .   +9 more
europepmc   +1 more source

Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58

ESC Heart Failure, EarlyView.
Abstract Background Galectin‐3 (Gal‐3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.
Paul M. Haller, Stephen D. Wiviott, David D. Berg, Petr Jarolim, Erica L. Goodrich, Deepak L. Bhatt, Ingrid Gause‐Nilsson, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Itamar Raz, Marc S. Sabatine, David A. Morrow   +12 more
wiley   +1 more source

Cross-sectional analysis of expressive and receptive language skills in Smith-Lemli-Opitz syndrome (SLOS). [PDF]

J Rare Dis (Berlin)
Morris SM, Tierney E.
europepmc   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

ESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge, Stefan James, John Deanfield, Niclas Eriksson, Mark de Belder, Monér Alchay, David Austin, Daniel A. Jones, Annica Ravn‐Fischer, Sofia Sederholm Lawesson, Nikunj Shah, Julian W. Strange, Karolina Szummer, Wilhelm Ridderstråle, Ehsan Parvaresh Rizi, Anna Maria Langkilde, Peter A. Johansson, Darren K. McGuire, Jonas Oldgren, Robert F. Storey   +19 more
wiley   +1 more source